Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis
19 April 2018 (08:30 - 18:00)
Organised by:
Abstract
Slides
About the speaker
University Clinic OWL, Bielefeld (Germany)
9 More presentations in this session
Access the full session
The Event
EuroPrevent 2018
19 April 2018
08:30 CET
